INTERIM REPORT Q4 2019
(WorldNews Politics)

INTERIM REPORT Q4 2019 Summary Financial overview October 1 - December 31, 2019 · Net sales amounted to SEK 0.0 M (0.0) · Loss for the period was SEK 244,9 M (loss: 112.0) · Loss per share, before and after dilution, was SEK 4.42 (loss: 2.54) · On December 31 cash and cash equivalents amounted to SEK 926.2 M (375.6) Significant events during the period October 1 - December 31, 2019 · In early December, an advisory meeting was held with the FDA is preparing for Oncopeptides`application for accelerated market approval · At the annual American Hematology Meeting (ASH) in December, Oncopeptides presented updated efficacy and safety data...